热门资讯> 正文
法雷奥制药报告第三季度业绩
2024-09-13 04:52
- Valeo Pharma press release (OTCQB:VPHIF): Q3 revenues of $12.6 million, down 11% from Q3-23, excluding XIIDRA, growth trend from continued business remains healthy at +9%, Q3-24 vs Q3-23
- Q3-24 adjusted EBITDA loss of $1.5 million compared to $2.5 million for Q3-23, down 40%.
- Enerzair and Atectura prescribing physicians reached, 4285 at the end of Q3-24, a 71% increase year-over-year.
- Total Enerzair and Atectura prescriptions for the 12 months ending July 31, 2024, exceeded 97,000, up 74% over the 12 months ending July 31, 2023.
More on Valeo Pharma
- Valeo Pharma appoints senior executive and Board of Director change
- Historical earnings data for Valeo Pharma
- Financial information for Valeo Pharma
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
